VVUS VIVUS Inc.

4.29
+0.12  (+3%)
Previous Close 4.17
Open 4.18
Price To Book -0.87
Market Cap 45,604,025
Shares 10,642,713
Volume 40,619
Short Ratio
Av. Daily Volume 144,437
Stock charts supplied by TradingView

NewsSee all news

  1. VIVUS Announces Acceptance of Qsymia Decentralized Marketing Authorization Application in Europe

    CAMPBELL, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a biopharmaceutical company, announced today that European regulatory agencies in Sweden, Denmark, Finland, Iceland,

  2. VIVUS Initiates Pay Down of Secured Debt and Announces Management Changes

    -Reduction of $48.6 million of Secured Debt will result in total interest savings of $10.5 million--Organizational change streamlines commercial operations- CAMPBELL, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) --

  3. VIVUS to Present at Upcoming Conferences

    CAMPBELL, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer at VIVUS, will present at the

  4. VIVUS to Share Qsymia® Safety and Efficacy Data with a Global Audience at ICOMES & AOCO 2019

    -Conference in Seoul provides opportunity to introduce an international audience to the clinical safety and benefits of Qsymia following its approval in the Republic of Korea- CAMPBELL, Calif., Aug. 27, 2019 (GLOBE

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved July 17, 2012.
Qnexa
Obesity
Approved Apr 27 2012. sNDA label change also approved 17 Sept 2014
Avanafil
Erectile dysfunction
Phase 1 trial completed July 2018.
VI-0106
Pulmonary arterial hypertension (PAH)

Latest News

  1. VIVUS Announces Acceptance of Qsymia Decentralized Marketing Authorization Application in Europe

    CAMPBELL, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a biopharmaceutical company, announced today that European regulatory agencies in Sweden, Denmark, Finland, Iceland,

  2. VIVUS Initiates Pay Down of Secured Debt and Announces Management Changes

    -Reduction of $48.6 million of Secured Debt will result in total interest savings of $10.5 million--Organizational change streamlines commercial operations- CAMPBELL, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) --

  3. VIVUS to Present at Upcoming Conferences

    CAMPBELL, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ:VVUS) (the "Company"), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer at VIVUS, will present at the

  4. VIVUS to Share Qsymia® Safety and Efficacy Data with a Global Audience at ICOMES & AOCO 2019

    -Conference in Seoul provides opportunity to introduce an international audience to the clinical safety and benefits of Qsymia following its approval in the Republic of Korea- CAMPBELL, Calif., Aug. 27, 2019 (GLOBE